2023
Disease-modifying therapies in multiple sclerosis: A focused review of rituximab
- Basic & Clinical Pharmacology & Toxicology
- DOI: 10/gswtz3
- PMID: 37563891
Peter AlpingMultiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
- Multiple Sclerosis
- DOI: 10/gr7j4x
- PMID: 37073483
Katharina Fink, Agnes Gorczyca, Peter Alping, Simon Englund, Susan Farmand, Annette M. Langer-Gould, Fredrik Piehl, Kyla McKay, Thomas Frisell, and Neda Razaz
2022
Pharmacoepidemiological Studies of Rituximab and Other Recent Therapies in Multiple Sclerosis
- Thesis
- Karolinska Institutet
- Sweden
Peter Alping
2021
Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Non-induction Therapies for Multiple Sclerosis
- Neurology
- DOI: 10/gjm86w
- PMID: 33514645
Peter Alping, Joachim Burman, Jan Lycke, Thomas Frisell, and Fredrik Piehl
2020
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
- Annals of Neurology
- DOI: 10/ggk2dq
- PMID: 32056253
Peter Alping, Johan Askling, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Magnus Vrethem, Tomas Olsson, Fredrik Piehl, and Thomas Frisell
2019
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
- JAMA Neurology
- DOI: 10/ggk2dr
- PMID: 31589278
Gustavo Luna, Peter Alping, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Magnus Vrethem, Tomas Olsson, Fredrik Piehl, and Thomas FrisellValidation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations
- Epidemiology
- DOI: 10/gfvpd7
- PMID: 30721167
Peter Alping, Fredrik Piehl, Annette Langer-Gould, Thomas Frisell, and undefined undefined
2016
Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
- Neurology
- DOI: 10/f3t5rz
- PMID: 27760868
Jonatan Salzer, Rasmus Svenningsson, Peter Alping, Lenka Novakova, Anna Björck, Katharina Fink, Protik Islam-Jakobsson, Clas Malmeström, Markus Axelsson, Mattias Vågberg, Peter Sundström, Jan Lycke, Fredrik Piehl, and Anders SvenningssonRituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients
- Annals of Neurology
- DOI: 10/f3rtc9
- PMID: 27038238
Peter Alping, Thomas Frisell, Lenka Novakova, Protik Islam-Jakobsson, Jonatan Salzer, Anna Björck, Markus Axelsson, Clas Malmeström, Katharina Fink, Jan Lycke, Anders Svenningsson, and Fredrik Piehl